Brussels (UNA-OIC) – The European Union Tuesday announced five therapeutics that could soon be available to treat patients against COVID-19 in the EU member states.
Four of these therapeutics are monoclonal antibodies, currently under review by the European Medicines Agency (EMA), said the European Commission in a statement.
Another one is an immunosuppressant, which has a marketing authorization that could be extended to include the treatment of COVID-19 patients.
The five products are in an advanced stage of development and have a high potential to be among the three new COVID-19 therapeutics to receive authorization by October 2021, the statement noted.
Stella Kyriakides, European Commissioner for Health and Food Safety, said: “Today we are taking the first step towards a broad portfolio of therapeutics to treat COVID-19.
“Whilst vaccination is progressing at increasing speed, the virus will not disappear and patients will need safe and effective treatments to reduce the burden of COVID-19,” she added.